Tudor Investment Corp’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-33,247
| Closed | -$1.65M | – | 4246 |
|
|
2025
Q4 | $1.65M | Buy |
33,247
+3,232
| +11% | +$157K | ﹤0.01% | 1948 |
|
|
2025
Q3 | $1.43M | Buy |
+30,015
| New | +$1.21M | ﹤0.01% | 2020 |
|
|
2024
Q4 | – | Sell |
-27,525
| Closed | -$858K | – | 3488 |
|
|
2024
Q3 | $858K | Buy |
+27,525
| New | +$859K | ﹤0.01% | 1719 |
|
|
2023
Q3 | – | Sell |
-27,769
| Closed | -$835K | – | 2845 |
|
|
2023
Q2 | $835K | Sell |
27,769
-16,137
| -37% | -$565K | 0.01% | 1408 |
|
|
2023
Q1 | $1.59M | Sell |
43,906
-36,801
| -46% | -$1.42M | 0.02% | 909 |
|
|
2022
Q4 | $2.88M | Sell |
80,707
-11,050
| -12% | -$384K | 0.06% | 449 |
|
|
2022
Q3 | $3.11M | Sell |
91,757
-19,426
| -17% | -$632K | 0.07% | 372 |
|
|
2022
Q2 | $3.21M | Sell |
111,183
-16,894
| -13% | -$484K | 0.08% | 300 |
|
|
2022
Q1 | $4.14M | Buy |
128,077
+41,964
| +49% | +$1.29M | 0.1% | 267 |
|
|
2021
Q4 | $2.51M | Buy |
86,113
+17,516
| +26% | +$531K | 0.04% | 531 |
|
|
2021
Q3 | $1.83M | Buy |
68,597
+57,797
| +535% | +$1.55M | 0.03% | 775 |
|
|
2021
Q2 | $333K | Sell |
10,800
-34,329
| -76% | -$1.05M | 0.01% | 1312 |
|
|
2021
Q1 | $1.18M | Buy |
+45,129
| New | +$1.26M | 0.02% | 758 |
|
|
2020
Q2 | – | Sell |
-29,620
| Closed | -$533K | – | 1405 |
|
|
2020
Q1 | $533K | Sell |
29,620
-13,627
| -32% | -$286K | 0.05% | 470 |
|
|
2019
Q4 | $1.03M | Buy |
43,247
+7,952
| +23% | +$193K | 0.05% | 486 |
|
|
2019
Q3 | $970K | Sell |
35,295
-10,970
| -24% | -$325K | 0.03% | 508 |
|
|
2019
Q2 | $1.53M | Buy |
46,265
+4,784
| +12% | +$164K | 0.04% | 411 |
|
|
2019
Q1 | $1.45M | Buy |
41,481
+5,764
| +16% | +$214K | 0.06% | 349 |
|
|
2018
Q4 | $1.19M | Buy |
+35,717
| New | +$1.54M | 0.02% | 337 |
|
|
2017
Q2 | – | Sell |
-10,548
| Closed | -$330K | – | 1357 |
|
|
2017
Q1 | $330K | Sell |
10,548
-17,029
| -62% | -$456K | 0.01% | 949 |
|
|
2016
Q4 | $696K | Buy |
27,577
+12,777
| +86% | +$285K | 0.02% | 540 |
|
|
2016
Q3 | $366K | Buy |
14,800
+300
| +2% | +$6.79K | 0.01% | 902 |
|
|
2016
Q2 | $295K | Sell |
14,500
-5,800
| -29% | -$103K | 0.01% | 1177 |
|
|
2016
Q1 | $310K | Sell |
20,300
-26,700
| -57% | -$348K | 0.01% | 1274 |
|
|
2015
Q4 | $632K | Buy |
47,000
+13,400
| +40% | +$207K | 0.02% | 720 |
|
|
2015
Q3 | $471K | Buy |
33,600
+8,700
| +35% | +$162K | 0.02% | 805 |
|
|
2015
Q2 | $423K | Sell |
24,900
-18,087
| -42% | -$257K | 0.01% | 876 |
|
|
2015
Q1 | $520K | Buy |
42,987
+29,021
| +208% | +$274K | 0.02% | 709 |
|
|
2014
Q4 | $116K | Buy |
+13,966
| New | +$117K | ﹤0.01% | 1358 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Tudor Investment Corp's SUPN Position: Q1 2026 in Review
Tudor Investment Corp sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 33,247 shares — an estimated $1.65M sold.
Tudor Investment Corp first reported a position in SUPN in Q4 2014 and held it in 29 quarters. The position peaked at $4.14M in Q1 2022. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Tudor Investment Corp reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Tudor Investment Corp sold 33,247 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.65M.
- Tudor Investment Corp first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 29 quarters.
- Tudor Investment Corp's Supernus Pharmaceuticals position peaked at $4.14M in Q1 2022.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.